Factor V Leiden (Inherited Thrombophilia)

Table of Contents

1. What is Factor V Leiden?
2. APC Resistance: The Functional Phenotype
3. Prevalence and Genetics
4. Thrombosis Risk Stratification
5. Factor V Leiden and Oral Contraceptives
6. Factor V Leiden and Pregnancy
7. Diagnosis and Laboratory Testing
8. Treatment and Long-Term Management
9. Family Screening and Genetic Counseling
10. Living with Factor V Leiden
11. Research Papers
12. Connections
13. Featured Videos

What is Factor V Leiden?

Factor V Leiden (FVL) is the most common inherited thrombophilia in people of European (Caucasian) descent — a genetic variant that makes the blood's clotting system overactive and substantially raises the lifetime risk of venous thromboembolism (VTE), the umbrella term for deep-vein thrombosis (DVT) and pulmonary embolism (PE).

The mutation lives in the F5 gene on chromosome 1q24.2. A single nucleotide substitution — c.1691G>A — changes amino acid 506 of coagulation Factor V from arginine to glutamine (p.Arg506Gln, also written R506Q). That one amino-acid swap at position 506 sits exactly at the site where activated protein C (APC) normally cuts and inactivates Factor Va. When APC cannot cleave at R506, Factor Va keeps working indefinitely, thrombin generation continues unchecked, and clots form far more readily than they should.

In plain terms: the mutation breaks the blood's built-in "off switch" for clotting, leaving the coagulation cascade running longer than it should after a clot is initiated. The condition follows an autosomal dominant inheritance pattern, meaning a single mutant copy from one parent is enough to raise clotting risk — though inheriting two copies (homozygous) raises it far more dramatically.

FVL was first described by Bertina and colleagues in 1994 when they identified the molecular basis of APC resistance and named the variant after the Dutch city of Leiden where the research was conducted.

Back to Table of Contents

APC Resistance: The Functional Phenotype

The function that FVL disrupts — APC resistance — was actually discovered before the mutation itself. In 1993, Bjorn Dahlback's group in Sweden noticed that plasma from certain thrombosis patients failed to prolong the clotting time when purified activated protein C was added. Normal plasma anticoagulates readily because APC degrades Factor Va (at R506 first, then R306 and R679); resistant plasma did not respond. This functional measurement became the APC resistance ratio test.

The standard test adds exogenous APC to a patient's plasma and measures the ratio of activated partial thromboplastin time (aPTT) with APC versus without. A low ratio (poor prolongation) indicates APC resistance. However, the standard test has significant confounders:

• Oral contraceptive pills (OCP) reduce protein S levels and increase Factor VIII, suppressing the ratio independently of FVL.
• Pregnancy physiologically elevates Factor VIII and reduces free protein S, causing spurious APC resistance.
• Antiphospholipid antibodies can interfere with phospholipid-dependent clotting tests.
• Liver disease reduces synthesis of multiple coagulation factors.
• Acute VTE itself elevates Factor VIII as a reactive protein, falsely reducing the ratio.

The modified (dilute) APC resistance test, which dilutes patient plasma in Factor V-deficient plasma before adding APC, largely eliminates these confounders and is more specific for the FVL mutation. Even so, genetic testing by PCR-based R506Q detection has become the gold standard because it is unambiguous, unaffected by concurrent medications or illness, and can be performed at any time.

Back to Table of Contents

Prevalence and Genetics

Factor V Leiden shows a striking population distribution that offers clues to its evolutionary history:

• Caucasians of European descent: heterozygous FVL (one mutant copy) is present in approximately 3–8% of the general population — making it by far the most common single-gene thrombophilia. Homozygous FVL (two mutant copies) affects roughly 0.01–0.02% of Caucasians.
• African populations: heterozygous FVL prevalence is approximately 1%, substantially lower than in Europeans.
• South and East Asian populations: prevalence is approximately 0.5% or lower; some East Asian populations show near-zero prevalence.
• Indigenous peoples of the Americas, sub-Saharan Africa, and indigenous Australia: FVL is largely or entirely absent, suggesting the mutation arose in a European ancestral population after the major population splits from Africa and before or during the peopling of Europe.

The mutation's high frequency in Europeans — despite its clear thrombotic risk — has led researchers to hypothesize a heterozygote advantage, most plausibly reduced peripartum hemorrhage. Women carrying FVL may have had better survival through childbirth in ancestral environments before surgical obstetrics existed, and this survival advantage was sufficient to offset the thrombotic risk.

Inheritance follows an autosomal dominant pattern. Each child of a heterozygous parent has a 50% chance of inheriting the mutation; both sexes are equally affected. Homozygous individuals have two copies (one from each parent) and face dramatically higher risk than heterozygotes. The second most common inherited thrombophilia, Prothrombin G20210A, acts synergistically with FVL when both are present.

Back to Table of Contents

Thrombosis Risk Stratification

Understanding FVL's actual risk numbers is essential — both to avoid unnecessary alarm in the many heterozygotes who will never have a clot, and to ensure appropriate vigilance in those at highest risk.

Population baseline: the annual incidence of VTE in the general population is approximately 1 per 1,000 person-years (roughly 0.1% per year). Over a lifetime, about 1 in 20 people will have a VTE event.

Heterozygous FVL:

• Lifetime VTE risk is approximately 3–8 times the population baseline — so roughly 0.3–0.8% per year.
• Despite this relative elevation, 50–60% of heterozygous FVL carriers never experience a VTE during their lifetime, particularly if they avoid additional triggering factors.
• The absolute annual risk remains low in the absence of other risk factors, which is why routine anticoagulation for asymptomatic heterozygotes is not recommended.

Homozygous FVL:

• VTE risk is approximately 50–80 times the population baseline.
• Most homozygous individuals will experience a VTE by age 40–50, often in the absence of obvious provoking factors.
• Homozygous FVL + additional thrombophilias (e.g., concomitant Prothrombin G20210A) produces the highest-risk phenotype short of severe antithrombin III deficiency.

Compound heterozygosity (one FVL allele + one Prothrombin G20210A allele) carries an intermediate risk between single heterozygous FVL and homozygous FVL.

Key modifying factors that add substantially to baseline FVL risk include: pregnancy and the postpartum period, oral contraceptive use, hormone replacement therapy, prolonged immobilization, major surgery, active malignancy, advanced age, obesity, and smoking. For heterozygotes, it is often the combination of FVL with one or more of these triggers — rather than FVL alone — that precipitates a first VTE event.

Back to Table of Contents

Factor V Leiden and Oral Contraceptives

The interaction between FVL and combined oral contraceptive pills (OCPs) is one of the most clinically important pharmacogenetic interactions in medicine. Each factor alone raises VTE risk; together, their effects are strongly synergistic — not merely additive.

• OCP alone (estrogen-containing): approximately 3–4 times the population VTE risk, primarily because estrogen increases circulating levels of Factors VII, VIII, X, and fibrinogen while reducing protein S and increasing APC resistance independently of FVL.
• FVL heterozygous alone: approximately 5–8 times the population VTE risk.
• FVL heterozygous + OCP combined: approximately 30–35 times the population VTE risk — a risk multiplication far exceeding what simple addition of the two individual risks would predict.

This synergy occurs because OCP-induced APC resistance stacks directly on top of the constitutive APC resistance from FVL. The net result is near-complete loss of the protein C anticoagulant pathway during OCP use in FVL carriers.

Clinical implications:

• Any young woman presenting with her first DVT or PE while on OCP should be evaluated for FVL and other thrombophilias.
• If FVL is confirmed, estrogen-containing contraceptives should be discontinued. The risk with progestogen-only pills or levonorgestrel/copper IUDs is substantially lower and generally acceptable for heterozygous FVL carriers.
• Routine thrombophilia screening before prescribing OCPs to all women is not currently recommended by major guidelines because the absolute VTE incidence remains low even for FVL heterozygotes and mass screening is cost-ineffective — but a personal or strong family history of VTE before age 50 is a reasonable indication to test first.
• Shared decision-making is essential: the individual woman's VTE history, family history, and preferences should guide contraceptive choice, not a one-size-fits-all algorithm.

Back to Table of Contents

Factor V Leiden and Pregnancy

Pregnancy is itself a profoundly hypercoagulable state — a physiological adaptation to reduce hemorrhage at delivery. Clotting factors I, VII, VIII, X, and XII all rise; protein S falls; fibrinolysis is suppressed. These changes peak in the third trimester and persist into the postpartum period. For women with FVL, pregnancy stacks a second pro-thrombotic burden on top of an already-resistant APC system.

VTE in pregnancy with FVL:

• Heterozygous FVL raises pregnancy-associated VTE risk approximately 7-fold compared with non-carriers.
• The absolute risk in heterozygotes without a personal VTE history is still modest — approximately 0.5–1% per pregnancy — meaning most pregnancies are uncomplicated.
• Homozygous FVL + pregnancy is a high-risk combination requiring prophylactic anticoagulation in virtually all cases.

Obstetric complications beyond VTE: FVL has also been associated with placenta-mediated pregnancy complications, including:

• Recurrent pregnancy loss (particularly second-trimester losses)
• Placental abruption
• Severe preeclampsia and HELLP syndrome
• Fetal growth restriction and small-for-gestational-age neonates
• Stillbirth (association is present but modest)

These complications are thought to arise from microthrombosis in placental intervillous spaces, reducing oxygen and nutrient delivery to the fetus. However, the strength of association varies across studies, and obstetric FVL complications are less robustly established than the VTE associations.

Low molecular weight heparin (LMWH) in pregnancy: LMWH does not cross the placenta and is the anticoagulant of choice during pregnancy. Whether asymptomatic FVL heterozygotes with no personal VTE history benefit from prophylactic LMWH during pregnancy is genuinely controversial. Most guidelines recommend prophylaxis only for women with a personal history of VTE or very strong family history. LMWH is continued or initiated postpartum (the period of highest absolute risk) for 6 weeks in most FVL-positive women who have had a prior VTE.

Back to Table of Contents

Diagnosis and Laboratory Testing

The diagnostic workup for suspected inherited thrombophilia — whether prompted by an unprovoked VTE, recurrent VTE, family history, or a pregnancy complication — involves functional screening followed by genetic confirmation.

Step 1 — Functional APC Resistance Assay:

• Standard or modified (dilute) APC resistance ratio.
• A low ratio indicates APC resistance but does not distinguish FVL from acquired causes.
• Can be falsely normal or falsely abnormal in many clinical settings (see APC Resistance section above).

Step 2 — Genetic Testing (Definitive):

• PCR-based testing for the R506Q (c.1691G>A) variant in the F5 gene.
• Definitively identifies heterozygous vs. homozygous status.
• Unaffected by anticoagulants, pregnancy, or acute illness.
• Can be performed at any time, before or after a VTE event, and regardless of ongoing anticoagulation.

Complete Thrombophilia Panel — additional tests often ordered simultaneously:

• Prothrombin G20210A mutation (second most common inherited thrombophilia)
• Protein C activity (functional assay)
• Protein S — total, free, and functional (free protein S most clinically relevant)
• Antithrombin III (AT-III) activity
• Lupus anticoagulant (two tests on two occasions 12 weeks apart)
• Anticardiolipin IgG and IgM antibodies
• Anti-beta-2-glycoprotein-1 IgG and IgM antibodies
• Homocysteine (fasting)

Critical timing consideration: Protein C, protein S, and antithrombin III are consumed or reduced during acute VTE and are also directly suppressed by anticoagulants (warfarin reduces vitamin-K-dependent proteins C and S; heparin may reduce AT-III). For accurate results, these functional assays should be drawn either:

• Before anticoagulation is started (during initial diagnostic workup), or
• At least 3 months after anticoagulation is stopped (when acute-phase effects have resolved).

In contrast, PCR-based genetic tests for FVL and Prothrombin G20210A are unaffected by anticoagulation and can be run at any time.

Back to Table of Contents

Treatment and Long-Term Management

Management of FVL depends critically on whether a VTE has occurred, the circumstances of that VTE (provoked vs. unprovoked), the patient's zygosity (heterozygous vs. homozygous), and individual bleeding risk.

Acute VTE treatment:

• Initial anticoagulation with low molecular weight heparin (LMWH) or unfractionated heparin, bridged (if using warfarin) or transitioned directly to a direct oral anticoagulant (DOAC).
• DOACs — particularly apixaban and rivaroxaban — are preferred over warfarin for most patients with FVL-associated VTE. They are oral, do not require INR monitoring, and have predictable pharmacokinetics. Dabigatran and edoxaban require a lead-in period of parenteral anticoagulation.
• Warfarin remains appropriate for patients with antiphospholipid syndrome, severe renal impairment, or specific patient preference.

Duration of anticoagulation — the critical management decision:

• Heterozygous FVL + first PROVOKED VTE (e.g., post-surgical, after prolonged immobilization, during pregnancy): 3–6 months of anticoagulation, same as for non-FVL provoked VTE. The recurrence rate after stopping is not substantially higher than in non-FVL patients with provoked VTE.
• Heterozygous FVL + first UNPROVOKED VTE: extended or indefinite anticoagulation should be considered. The annual recurrence risk off anticoagulation is approximately 10–15%, and recurrence in FVL heterozygotes may be higher than in the general unprovoked VTE population.
• Heterozygous FVL + recurrent VTE (two or more events): indefinite anticoagulation is recommended in most guidelines.
• Homozygous FVL + any VTE: indefinite anticoagulation is standard practice given the very high recurrence risk.

Asymptomatic FVL without VTE history:

• Routine anticoagulation is not recommended — the absolute annual VTE risk in heterozygotes is low, and the long-term bleeding risk from indefinite anticoagulation is meaningful.
• Targeted short-term prophylaxis is appropriate for high-risk situations: major surgery (LMWH perioperatively), prolonged hospitalization or immobility, long-haul air travel (hydration, mobility, compression stockings, and for highest-risk patients, LMWH).
• Estrogen-containing contraceptives and postmenopausal HRT should be avoided or used with extreme caution.
• Education about VTE warning signs and when to seek emergency care is critical.

Monitoring: patients on warfarin require regular INR monitoring targeting 2.0–3.0. Patients on DOACs require periodic renal function assessment (especially for rivaroxaban and apixaban, which are renally cleared). All anticoagulated patients should be counseled on bleeding precautions, drug interactions, and the importance of not stopping anticoagulation abruptly without physician guidance.

Back to Table of Contents

Family Screening and Genetic Counseling

Because FVL is inherited, identifying it in one family member raises the question of testing for first-degree relatives. Guidelines on this are nuanced:

Arguments for family screening:

• Identifying FVL in an asymptomatic relative allows targeted counseling about contraception choices, pregnancy management, and situational prophylaxis.
• First-degree relatives of FVL homozygotes have a 50% chance of heterozygosity and should generally be offered testing.
• A positive result in a young woman who would otherwise have started combined OCPs may prompt a safer contraceptive choice and prevent a VTE.

Arguments for caution:

• Most heterozygous FVL carriers will never have a VTE, so a positive test result can generate significant anxiety without commensurate benefit.
• A positive test may affect life insurance or long-term care insurance eligibility in some jurisdictions.
• Knowledge of FVL carrier status is not uniformly associated with improved clinical outcomes in large population studies.
• Routine population screening is not cost-effective given the low absolute risk in heterozygotes.

Who benefits most from testing: relatives of homozygous probands; relatives of individuals with recurrent VTE or early unprovoked VTE; women of childbearing age who are planning pregnancy or considering hormonal contraception; individuals facing major elective surgery or prolonged immobilization. In these contexts, genetic counseling before and after testing ensures that results are interpreted accurately and do not cause unwarranted harm.

Back to Table of Contents

Living with Factor V Leiden

For the majority of heterozygous FVL carriers — particularly those who have not had a VTE — day-to-day life does not require major restrictions. The goal is informed awareness, not fear.

Lifestyle recommendations:

• Stay active: regular movement is one of the most effective ways to reduce VTE risk. Sedentary behavior — especially prolonged sitting — promotes venous stasis in the leg veins, which is the first of Virchow's triad contributing to DVT.
• Long-haul travel: for flights or drives over 4–6 hours, take regular walking breaks, stay well hydrated, and consider graduated compression stockings (knee-length, 15–30 mmHg). Those with prior VTE or additional risk factors should discuss LMWH prophylaxis with their physician before travel.
• Maintain healthy weight: obesity significantly amplifies VTE risk, including in FVL carriers.
• Avoid smoking: smoking promotes endothelial damage, a second component of Virchow's triad.
• Know the warning signs: sudden calf pain, redness, and swelling suggest DVT; sudden shortness of breath, chest pain, or hemoptysis suggest PE. Both are medical emergencies requiring immediate evaluation.
• Medical alert: carrying documentation of FVL status ensures that emergency and surgical teams are informed. Many patients wear a medical alert bracelet.
• Inform all healthcare providers: FVL status should be part of any surgical pre-assessment, obstetric booking, and primary care record.

The psychological burden of an inherited thrombophilia diagnosis is real. Patients often worry about passing the mutation to children, about pregnancy risks, and about the possibility of a life-threatening clot. Access to a hematologist or thrombosis specialist, clear written information, and peer support groups (such as the National Blood Clot Alliance in the United States) can substantially reduce this burden.

Back to Table of Contents

Research Papers

1. Bertina RM, Koeleman BP, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994;369(6475):64–67. PMID 8177224 — Original identification of the Factor V Leiden R506Q mutation as the molecular cause of APC resistance.
2. Dahlback B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C. Proc Natl Acad Sci USA. 1993;90(3):1004–1008. PMID 8430378 — Discovery of the APC resistance phenotype in thrombophilic families, preceding molecular characterization.
3. Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisenberg PR, Miletich JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med. 1995;332(14):912–917. PMID 7877648 — Physicians Health Study data establishing FVL as a risk factor for VTE in a large male cohort.
4. Vandenbroucke JP, Koster T, Briet E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet. 1994;344(8935):1453–1457. PMID 7968070 — Landmark paper demonstrating the synergistic 30-fold VTE risk from FVL combined with oral contraceptives.
5. Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood. 1995;85(6):1504–1508. PMID 7888675 — Quantifies the dramatically elevated VTE risk in homozygous versus heterozygous FVL carriers.
6. Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet. 1995;346(8983):1133–1134. PMID 7475606 — Population genetic study showing the unique European distribution of FVL and its near-absence in African and Asian populations.
7. Middeldorp S, van Hylckama Vlieg A. Does thrombophilia testing help in the clinical management of patients? Br J Haematol. 2008;143(3):321–335. PMID 18798889 — Comprehensive critical review of whether thrombophilia testing changes patient outcomes and when it is clinically useful.
8. Simioni P, Prandoni P, Lensing AW, et al. The risk of recurrent venous thromboembolism in patients with an Arg506-->Gln mutation in the gene for factor V (factor V Leiden). N Engl J Med. 1997;336(6):399–403. PMID 9010143 — Prospective cohort study quantifying recurrent VTE rates in FVL patients off anticoagulation and informing anticoagulation duration decisions.
9. Grody WW, Griffin JH, Taylor AK, Korf BR, Heit JA; ACMG Factor V Leiden Working Group. American College of Medical Genetics consensus statement on factor V Leiden mutation testing. Genet Med. 2001;3(2):139–148. PMID 11280953 — Evidence-based consensus on who should be tested for FVL and how results should guide management.
10. Robertson L, Wu O, Langhorne P, et al. Thrombophilia in pregnancy: a systematic review. Br J Haematol. 2006;132(2):171–196. PMID 16398652 — Systematic review quantifying the association between FVL and obstetric complications including recurrent pregnancy loss, abruption, and fetal growth restriction.
11. Kujovich JL. Factor V Leiden thrombophilia. Genet Med. 2011;13(1):1–16. PMID 21116184 — Comprehensive GeneReviews entry covering genetics, prevalence, pathophysiology, diagnosis, and management of FVL.
12. Kearon C, Akl EA, Ornelas J, et al. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest. 2016;149(2):315–352. PMID 26867832 — American College of Chest Physicians guideline providing evidence-based recommendations on anticoagulation duration in thrombophilia including FVL.

Back to Table of Contents

Connections

• Deep-Vein Thrombosis
• Antiphospholipid Syndrome
• Disseminated Intravascular Coagulation
• Thrombocytopenia
• Heparin-Induced Thrombocytopenia
• Aplastic Anemia
• Hemophilia
• Polycythemia Vera
• Pulmonary Embolism
• Complete Blood Count
• Vitamin K
• Hematology Conditions

Back to Table of Contents

Featured Videos